JAK1-IN-21
JAK1-IN-21, biotin-conjugated isoxazole derivative, is a JAK1 inhibitor. JAK1-IN-21 directly engages and stabilizes JAK1, reduces the phosphorylation of JAK1, STAT1 and AKT, induces apoptotic marker cleavage (PARP, Caspase-3, Caspase-7) and exhibits broad-spectrum antiproliferative activity against cancer cells. JAK1-IN-21 can be used for the study of liver cancer, prostate cancer, and breast cancer.
For research use only. We do not sell to patients.
- Formula: C34H34ClN3O5S
- Molecular Weight:632.17
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Caspase Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
JAK1 |
STAT1 |
Akt1 |
Caspase-3 |
Caspase-7 |
Cellular Effect
In Vitro
JAK1-IN-21 (C160) (0.3-10 μM; 72 h) inhibits the proliferation of Mahlavu, SNU475, C4-2, DU145, PC3, T47D and MDA-MB-231 cells, with IC50 values of 2.73, 1.48, 0.89, 1.39, 1.41, 0.52 and 3.05 μM, respectively[1].
JAK1-IN-21 (1-5 μM; 24-48 h) causes pronounced inhibition of STAT1 phosphorylation and markedly reduces phosphorylated JAK1 levels in Mahlavu, DU145 and C4-2 cells[1].
JAK1-IN-21 (10 μM; 30 min) results in a clear, dose-dependent protection of JAK1 from Pronase-mediated digestion[1].
JAK1-IN-21 (5 μM; 1 h) increases the thermal stability of JAK1 in Mahlavu cell lysates in a CETSA assay[1].
JAK1-IN-21 (1-5 μM; 24 h) induces robust cleavage of PARP, Caspase-3 and Caspase-7 in Mahlavu, DU145 and C4-2 cells[1].
JAK1-IN-21 (120 min) exhibits great stability in human plasma retaining 89% of the parent compound[1].
JAK1-IN-21 (0.3-10 μM; 3 days) suppresses C4-2 spheroid growth, resulting in smaller spheroid size, disrupted spheroid morphology and increased signs of apoptosis[1].
JAK1-IN-21 (0.75-5 μM; 10 days) produces a pronounced antiproliferative effect in T47D spheroids[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Mahlavu, SNU475, C4-2, DU145, PC3, T47D, MDA-MB-231 and MCF10A cells
-
Concentration:0.3-10 μM
-
Incubation Time:72 h
-
Result:Inhibited the proliferation of T47D, C4-2, DU145, PC3, SNU475, Mahlavu, and MDA-MB-231 cells, with IC50 values of 0.52, 0.89, 1.39, 1.41, 1.48, 2.73, and 3.05 μM, respectively.
Showed weaker inhibitory activity in MCF10A cells, with an IC50 of 6.10 μM.
-
Cell Line:Mahlavu, DU145, and C4-2 cells
-
Concentration:1 μM, 5 μM
-
Incubation Time:24 h, 48 h
-
Result:Robustly inhibited the phosphorylation of JAK1 and STAT1, thereby suppressing JAK/STAT signaling.
-
Cell Line:Mahlavu cell lysates
-
Concentration:10 μM
-
Incubation Time:30 min
-
Result:Resulted in a clear, dose-dependent protection of JAK1 from Pronase-mediated digestion.
-
Cell Line:Mahlavu cell lysates
-
Concentration:5 μM
-
Incubation Time:1 h
-
Result:Increased the thermal stability of JAK1.
Consistently preserved higher levels of soluble JAK1 between 58 and 62 °C.
-
Cell Line:Mahlavu, DU145 and C4-2 cells
-
Concentration:1 μM, 5 μM
-
Incubation Time:24 h
-
Result:Induced robust cleavage of PARP, Caspase-3 and Caspase-7.
Exhibited significant apoptotic responses in Mahlavu and C4-2 cells even at low doses.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Wild-type zebrafish larvae at 2 dpf[1]
-
Dosage:2 μM, 5 μM, 10 μM or 10 μM, 30 μM, 50 μM
-
Administration:72 h; daily medium renewal
-
Result:Resulted in no morphological abnormalities or developmental defects at concentrations comparable to those used in cellular assays (2, 5, 10 μM).
Did not cause lethality at up to 50 μM.
Displayed normal morphology with no signs of toxicity even at 50 μM.
Chemical Information
-
Molecular Weight 632.17
-
Formula C34H34ClN3O5S
-
SMILES
O=C(OCC1=NOC(C2=CC=C(OCC3=CC=CC=C3C)C=C2)=C1C4=CC=C(Cl)C=C4)CCCCC5SCC(C5N6)NC6=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Liver Cancer Modeling
Liver cancer can be classified into primary liver cancer and secondary liver cancer. Secondary liver cancer is the metastatic liver cancer. Primary liver cancer includes hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC) and fibrolamellar HCC, of which HCC is the most common form, accounting for approximately 90% of primary liver cancers[1]. HCC mouse models include chemical agent-induced models, transplanted tumor models, and genetic engineered models.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)